Co-Diagnostics, Inc.

During the three months ended December 31, 2025, none of our directors or officers adopted orterminated a “Rule 10-b5-1 trading arrangement” or “non-Rule 10-b5-1 trading arrangement” as each term is identified in Item 408 of Regulation S-K.

On March 31, 2026, the Company approved and initiated a workforce reduction as part of an ongoing effort to align its cost structure with current business conditions and strategic priorities. The workforce reduction impacts approximately 26% of the Company’s employees across multiple functions. The Company expects that the reduction in force will be substantially completed by April 15, 2026. The Company does not expect to incur material charges in connection with this workforce reduction, as affected employees will receive only compensation through their respective termination dates and payment of accrued obligations in accordance with existing Company policies and applicable law. Accordingly, the Company does not currently anticipate recognizing significant restructuring or severance-related expenses associated with this action. The Company expects that the workforce reduction will result in a reduction of operating expenses beginning in the second quarter of 2026. The Company continues to evaluate its cost structure and may take additional actions as deemed appropriate to support its long-term strategic objectives.